إصدارات الهيئة

نشرات اليقظة الدوائية

أولاً: التوعية الدوائية: 

Content Issue date Issue
  • Alert: Unictam Vial Counterfeit
  • Reminder of General Measures to Prevent the Nephrotoxicity Risk with High dose Methotrexate
  • Local Case Report: Paclitaxel - Convulsions and Coma
  • EPVC News
4/2022

(147) Newsletter-Hundred Forty Seven April 2022

  • DHPC:Dapagliflozin 5mg Should No Longer be Used for the Treatment of Type 1 Diabetes Mellitus
  • Local Case Report: Alendronic Acid - Case of Osteonecrosis of the Jaw
  • EPVC News
3/2022

(146) Newsletter-Hundred Forty Six March 2022

  • DHPC: Donepezil-QTc interval extension and Torsade de Pointes
  • Local Case Report: Tranexamic acid - Case of Convulsions
  • EPVC News
2/2022

(145) Newsletter-Hundred Forty five February 2022

  • Pholcodine Containing Antitussive Drugs and Risk of Allergic Reaction to Neuromuscular Blocking Agents
  • DHPC: Glatiramer acetate Rare Cases of Severe Liver Damage
  • Local Case Report: A case of Guillain-Barre syndrome following Janssen COVID-19 vaccine
  • EPVC News
1/2022

(144) Newsletter-Hundred Forty four January 2022

  • DHPC: Amiodarone Hydrochloride 50 mg/ml Concentrate for Solution for Injection/Infusion Potential for crystallization
  • Local Case Report: Case of Drug Dependence and Overdose Following Xylometazoline Nasal Drops Prolonged Administration
  • EPVC News
12/2021

(143) Newsletter-Hundred Forty three Deecember 2021

  • DHPC: COVID-19  mRNA  Vaccine Comirnaty: Risk of Myocarditis and Pericarditis.
  • Local Case  Report:  A  Case  of Drug Abuse Resulted in Acute Renal  Injury,  Cardiomegaly, Muscle Weakness,  Ulcers,  Sepsis  and  Finally  Death  Following  Paraffin Oil, Anabolic Steroids and Synthol Local Administration
11/2021

(142) Newsletter-Hundred Forty two November 2021

  • COVID-19 Vaccine Astra-Zeneca: Warning for Guillain-Barre syndrome
  • Topical corticosteroids: Information on the risk of topical steroid withdrawal reactions
  • EPVC News
10/2021 (141) Newsletter-Hundred Forty One October 2021
  • Colchicine: High risk of fatality with Colchicine over-dose
  • Fingolimod: Updated advice about the risks of serious liver injury and herpes meningoencephalitis
  • EPVC News
09/2021 (140) Newsletter-Hundred Forty
September 2021
  • Bendamustine: Risk of nonmelanoma skin cancer
  • Levodopa DHPC 2
  • Local Case Report: Lamivudine and Sulipride
08/2021 (139) Newsletter-Hundred Thirty-nine
August 2021
  • Obeticholic acid: Restriction of use
  • Local Case Report: Fluorouracil
  • EPVC News
07/2021

(138) Newsletter-Hundred Thirty-eight
July 2021

  • Polyethylene glycol (PEG) laxatives and starch-based thickeners: risk of aspiration
  • Local Case Report: Interaction between Warfarin and Naproxen
  • EPVC News
06/2021

(137) Newsletter-Hundred Thirty-seven
June 2021

  • Bupropion: risk of serotonin syndrome
  • Local Case Report: Warfarin
05/2021

(136) Newsletter-Hundred Thirty-six
May 2021

  • Erythromycin: Update on Risk of Infantile Hypertrophic Pyloric Stenosis
  • Local Case Report: Ceftriaxone
  • EPVC News
04/2021

(135) Newsletter-Hundred Thirty-five
April 2021

  • Erythromycin Cardiac Risk and Interaction with Rivaroxaban
  • Local Case Report: Furosemide
  • EPVC News
03/2021

(134) Newsletter-Hundred Thirty-four
March 2021

  • SSRI/SNRI risk of post-partum hemorrhage
  • Local Case Report: Sildenafil
  • EPVC News
02/2021

(133) Newsletter-Hundred Thirty-three
February 2021

  • DHPC for Dimethyl Fumarate
  • Safety Communication for Emicizumab
  • Local Case Report: Cyclizine
  • EPVC News
01/2021

(132) Newsletter-Hundred Thirty-two
January 2021

 

ثانياً: خطابات موجهة لمقدمى الخدمات الصحية:

Content Issue date Issue
  • Increased risk of Cardiovascular Events & Cardiovascular Mortality when Hydroxychloroquine or Chloroquine used with Macrolide antibiotics
4/2022

DHPC Azithromycin interaction with hydroxychloroquine

  • PAXLOVID Emergency Use Authorization (EUA) dosing and dispensing in moderate
    renalimpairment, and risk of serious adverse reactions due to drug interactions
3/2022

DHPC Paxlovid used in Covid

  • Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
3/2022

DHPC Anagrelide

  • Mavenclad (Cladribine) – risk of serious liver injury and new recommendations about liver function monitoring
3/2022

DHPC Cladribine

  • Infliximab: Use of live vaccines in infants exposed in utero or during breastfeeding
3/2022

DHPC Infliximab

  • Levocetirizine shouldn’t be used in children less than 2 years
2/2022

DHPC Levocetirizine

  • Important Safety Information Regarding Use of Molnupiravir in Pregnancy and Individuals of Childbearing Potential
2/2022

DHPC Molnupiravir

  • Octreotide Solution for Subcutaneous injection and intravenous infusion: Risk of atrioventricular block
2/2022

DHPC Octreotide

  • Olsalazine – Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP)
2/2022

DHPC Olsalazine

  • Donepezil-QTc interval extension and Torsade de Pointes
1/2022

DHPC Donepezil

  • Glatiramer Acetate: Rare cases of severe liver damage
1/2022

DHPC Glatiramer

  • Amiodarone Hydrochloride 50 mg/ml concentrate for solution for
    Injection/Infusion - Potential for crystallisation
1/2022 DHPC Amiodarone
  • Dapagliflozin 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus
1/2022 DHPC Dapagliflozin
  • Dinoprostone: Add A Restriction On Use And Update Of Dosage Recommendations, Warnings And Especially Adding Recommendations On The Risks Of Hyperstimulation Uterine, Uterine Rupture And Fetal / Neonatal Mortality
1/2022

DHPC Dinoprostone

  • COVID-19 mRNA Vaccine Spikevax (previously Moderna): risk of myocarditis and pericarditis
11/2021

DHPC for Moderna concerning pericarditis

  • COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditis
11/2021

COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditi

  • COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding
10/2021

COVID-19 Vaccine AstraZeneca Risk of thrombocytopenia

  • COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)
10/2021

COVID-19 Vaccine Janssen Risk for immune thrombocytopenia

  • COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
6/2021 COVID-19 Vaccine AstraZeneca contraindication
  • It was noted that the dosing information (specifically the timing of dosing with respect to food) in the product information for the levodopa-containing products was not optimal: it did not make clear that dosing without food is possible, and maybe preferable for some patients. 
6/2021 Updating Dosing Information Levodopa
  • COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome
  • Capillary leak syndrome (CLS)
  • Thrombosis with thrombocytopenia syndrome(TTS)
6/2021

J&J Covid 19 Vaccine
Risk Of Capillary Leak Syndrome And TTS

  • COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with
    thrombocytopenia — Updated information .
6/2021

Astrazeneca Covid 19 Vaccine Risk Of TTS update June 2021

  • Tofacitinib: initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors.
4/2021

Tofacitinib Updated safety information

  • COVID-19 Vaccine AstraZeneca: Risk of coagulation disorders with or
    without thrombocytopenia
4/2021

AstraZeneca Covid 19 Vaccine Risk Of TTS April 2021

  • As the leaflets available in the packs of Leflunomide tablets are currently undergoing important safety updates, we would like to inform you of these important safety updates till their implementation in packs.
3/2021

Leflunomide Safety Updates

 

جميع الحقوق محفوظة © 2021